Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia
- PMID: 26405111
- PMCID: PMC4769204
- DOI: 10.1681/ASN.2015020157
Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia
Abstract
Preeclampsia is a devastating complication of pregnancy. Soluble Fms-like tyrosine kinase-1 (sFlt-1) is an antiangiogenic protein believed to mediate the signs and symptoms of preeclampsia. We conducted an open pilot study to evaluate the safety and potential efficacy of therapeutic apheresis with a plasma-specific dextran sulfate column to remove circulating sFlt-1 in 11 pregnant women (20-38 years of age) with very preterm preeclampsia (23-32 weeks of gestation, systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, new onset protein/creatinine ratio >0.30 g/g, and sFlt-1/placental growth factor ratio >85). We evaluated the extent of sFlt-1 removal, proteinuria reduction, pregnancy continuation, and neonatal and fetal safety of apheresis after one (n=6), two (n=4), or three (n=1) apheresis treatments. Mean sFlt-1 levels were reduced by 18% (range 7%-28%) with concomitant reductions of 44% in protein/creatinine ratios. Pregnancy continued for 8 days (range 2-11) and 15 days (range 11-21) in women treated once and multiple times, respectively, compared with 3 days (range 0-14) in untreated contemporaneous preeclampsia controls (n=22). Transient maternal BP reduction during apheresis was managed by withholding pre-apheresis antihypertensive therapy, saline prehydration, and reducing blood flow through the apheresis column. Compared with infants born prematurely to untreated women with and without preeclampsia (n=22 per group), no adverse effects of apheresis were observed. In conclusion, therapeutic apheresis reduced circulating sFlt-1 and proteinuria in women with very preterm preeclampsia and appeared to prolong pregnancy without major adverse maternal or fetal consequences. A controlled trial is warranted to confirm these findings.
Keywords: clinical trial; preeclampsia; pregnancy; sFlt-1; therapeutic apheresis; vascular endothelial growth factor.
Copyright © 2016 by the American Society of Nephrology.
Figures
Comment in
-
Apheresis to Treat Preeclampsia: Insights, Opportunities and Challenges.J Am Soc Nephrol. 2016 Mar;27(3):663-5. doi: 10.1681/ASN.2015070794. Epub 2015 Sep 24. J Am Soc Nephrol. 2016. PMID: 26405110 Free PMC article. No abstract available.
Similar articles
-
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia.Circulation. 2011 Aug 23;124(8):940-50. doi: 10.1161/CIRCULATIONAHA.111.034793. Epub 2011 Aug 1. Circulation. 2011. PMID: 21810665 Clinical Trial.
-
Treatment of very preterm preeclampsia via heparin-mediated extracorporeal LDL-precipitation (H.E.L.P.) apheresis: The Freiburg preeclampsia H.E.L.P.-Apheresis study.Pregnancy Hypertens. 2018 Apr;12:136-143. doi: 10.1016/j.preghy.2018.04.007. Epub 2018 Apr 11. Pregnancy Hypertens. 2018. PMID: 29858106 Clinical Trial.
-
Therapeutic plasma exchange and dextran-sulfate plasma adsorption as extracorporeal treatments of extremely preterm preeclampsia with fetal growth restriction.J Clin Apher. 2021 Aug;36(4):595-605. doi: 10.1002/jca.21899. Epub 2021 Apr 13. J Clin Apher. 2021. PMID: 33847403
-
A Review of Angiogenic Imbalance in HIV-Infected Hypertensive Disorders of Pregnancy.Curr Hypertens Rep. 2019 Jul 24;21(9):69. doi: 10.1007/s11906-019-0970-7. Curr Hypertens Rep. 2019. PMID: 31342170 Review.
-
Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia.Ann Biol Clin (Paris). 2016 Jun 1;74(3):259-67. doi: 10.1684/abc.2016.1158. Ann Biol Clin (Paris). 2016. PMID: 27237799 Review. English.
Cited by
-
Exploiting sweet relief for preeclampsia by targeting autophagy-lysosomal machinery and proteinopathy.Exp Mol Med. 2024 May;56(5):1206-1220. doi: 10.1038/s12276-024-01234-x. Epub 2024 May 17. Exp Mol Med. 2024. PMID: 38760513 Free PMC article.
-
An Examination of the Effect of Aspirin and Salicylic Acid on Soluble Fms-like Tyrosine Kinase-1 Release from Human Placental Trophoblasts.Cells. 2024 Jan 6;13(2):113. doi: 10.3390/cells13020113. Cells. 2024. PMID: 38247805 Free PMC article.
-
Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia.Front Med (Lausanne). 2023 Sep 20;10:1190446. doi: 10.3389/fmed.2023.1190446. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37799590 Free PMC article.
-
New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations.Int J Mol Sci. 2023 Jul 28;24(15):12100. doi: 10.3390/ijms241512100. Int J Mol Sci. 2023. PMID: 37569476 Free PMC article. Review.
-
Biology and therapeutic targeting of vascular endothelial growth factor A.Nat Rev Mol Cell Biol. 2023 Nov;24(11):816-834. doi: 10.1038/s41580-023-00631-w. Epub 2023 Jul 25. Nat Rev Mol Cell Biol. 2023. PMID: 37491579 Review.
References
-
- McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ: Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 156: 918–930, 2008 - PubMed
-
- Sibai BM: Prevention of preeclampsia: a big disappointment. Am J Obstet Gynecol 179: 1275–1278, 1998 - PubMed
-
- Walker JJ: Pre-eclampsia. Lancet 356: 1260–1265, 2000 - PubMed
-
- Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, Shackelford KA, Steiner C, Heuton KR, Gonzalez-Medina D, Barber R, Huynh C, Dicker D, et al. Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384: 980–1004, 2014 - PMC - PubMed
-
- Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672–683, 2004 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous